Pharmacogenomics of opioids: an investigation of the genetic determinants of variability in analgesic response to opioids

Submission date	Recruitment status	Prospectively registered
30/09/2004	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
30/09/2004	Completed	Results
Last Edited	Condition category	Individual participant data
19/10/2016	Signs and Symptoms	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Julia Riley

Contact details

Palliative Care
Royal Marsden NHS Trust
Fulham Road
Chelsea
London
United Kingdom
SW3 6JJ
+44 (0)20 7352 8171
Julia.Riley@rmh.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0258123628

Study information

Scientific Title

Pharmacogenomics of opioids: an investigation of the genetic determinants of variability in analgesic response to opioids

Study objectives

The primary aim of this research project is to test the hypothesis that inter-subject variability in response to morphine is determined by polymorphisms in the u-opioid receptor gene.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Analgesic response to opioids

Interventions

Randomised, blinded (Phase 2).

Each subject will act as their own control. On visit one, subjects will be randomised to receive either intravenous morphine or intravenous saline (placebo). They will then cross-over to receive placebo or morphine respectively at the second visit.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/10/2003

Completion date

01/10/2005

Eligibility

Key inclusion criteria

Total number RMH patients 100

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

100

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/10/2003

Date of final enrolment

01/10/2005

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Palliative Care

London United Kingdom SW3 6JJ

Sponsor information

Organisation

Department of Health

Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL

Sponsor type

Government

Website

http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type

Government

Funder Name

The Royal Marsden NHS Trust

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration